FDA Okays First Rapid HCV Test
Posted on June 26th, 2010 by Health News
WASHINGTON (MedPage Today) — The FDA has approved the first rapid blood hepatitis C virus test for patients 15 and older.
No Comments »
Filed under: General Health News
Health News
News about health, pharmacy and medical care
U of Michigan to Reject Industry Sponsors for CME
Posted on June 26th, 2010 by Health News
Industry funding for CME programs will no longer be welcome at the University of Michigan come next January, its medical school announced.
No Comments »
Filed under: General Health News
FDA Okays First Rapid HCV Test
Posted on June 26th, 2010 by Health News
WASHINGTON (MedPage Today) — The FDA has approved the first rapid blood hepatitis C virus test for patients 15 and older.
No Comments »
Filed under: Pharmacy News
CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial
Posted on June 26th, 2010 by Health News
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced dosing of the first patient with CRMD-001 (a proprietary formulation of deferiprone) in a randomized, double-blind, placebo-controlled clinical trial.
No Comments »
Filed under: Pharmacy News
Sanofi-aventis’ Phase I clinical trial with SAR650984 triggers $1M milestone payment to ImmunoGen
Posted on June 26th, 2010 by Health News
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that sanofi-aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. This event triggers a $1 million milestone payment to ImmunoGen.
No Comments »
Filed under: Pharmacy News
Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease initiated
Posted on June 26th, 2010 by Health News
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the commencement of a Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease. The company also announced that GMI-1070 has received Fast Track designation from the U.S. Food [...]
No Comments »
Filed under: Pharmacy News
New CDC Guidelines Prefer Use Of Blood Tests, Including QuantiFERON®-TB, To Diagnose Tuberculosis Infection In Certain Populations
Posted on June 26th, 2010 by Health News
Today the United States (U.S.) Centers for Disease Control and Prevention (CDC) issued new and important guidelines on the detection of Mycobacterium tuberculosis infections, the causative agent of tuberculosis (TB)…
No Comments »
Filed under: Pharmacy News
Neuro Kinetics Awarded Phase II SBIR Grant For Diabetic Retinopathy Innovation
Posted on June 26th, 2010 by Health News
Neuro Kinetics, Inc. (NKI), manufacturers of noninvasive medical diagnostic equipment used worldwide to test for vestibular and neurological conditions, said that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant to further the company’s development of a new ophthalmic screening device and testing protocols for the detection and diagnosis of diabetic [...]
No Comments »
Filed under: Pharmacy News
Nektar Announces Dosing Of First Patients In Phase 1 Clinical Study Of NKTR-102 In Combination With 5-Fluorouracil/Leucovorin
Posted on June 26th, 2010 by Health News
Nektar Therapeutics (Nasdaq: NKTR) announced that the first patients have been dosed in a new Phase 1 dose-escalation clinical study to evaluate NKTR-102, the company’s lead oncology compound, in combination with 5-fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers…
No Comments »
Filed under: Pharmacy News
New Head-to-Head Phase 3 Study Evaluated Systolic Blood Pressure Reduction Of Investigational Compound Azilsartan Medoxomil Compared To Valsartan
Posted on June 26th, 2010 by Health News
Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced results from a pivotal phase 3 study of azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) that demonstrated greater 24-hour mean systolic blood pressure (SBP) and clinic SBP reduction at 24 weeks compared to the commonly prescribed ARB, valsartan…
No Comments »
Filed under: Pharmacy News
